Anti-HER2 CD4+ T-Helper Type 1 Immune Response is Superior to Breast MRI for Assessing Response to Neoadjuvant Therapy in Patients with HER2-Positive Breast Cancer
暂无分享,去创建一个
B. Czerniecki | R. Mick | Shuwen Xu | N. Nocera | C. Fisher | E. McDonald | J. Datta | Lucy M. Cruz | L. Cruz | Rosemarie Mick